G-Medical Net will be designated a supervised stock, under review, from June 1 after it said it still could not confirm compliance with the Tokyo Stock Exchange Growth market's market-capitalisation maintenance standard by May 31, the end of its improvement period. The company has applied to move to the Standard market instead.
That matters because the designation does not automatically stop trading. G-Medical Net said trading on the Growth market will continue as normal after June 1, and that the supervised-review label would be lifted if the exchange approves its market-change application.
In a separate disclosure, the company said its board approved the application on May 28 and that it submitted it on May 29. It also said, based on its own calculations, that it meets the Standard market's listing-review thresholds: 15,281 shareholders, 58,087 tradable-share units, ¥1.5 billion of tradable-share market value, a 53.91% tradable-share ratio, and positive net assets. The disclosed thresholds are 400 shareholders, 2,000 units, ¥1 billion, 25.0%, and positive net assets.
The catch is that those Standard market figures are company estimates, using shareholder-distribution data as of November 30, 2025 and the May 28 closing price. Until Tokyo Stock Exchange finishes its review, investors have clarity on one point and uncertainty on another: the shares keep trading, but the market switch is not yet approved.